Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054864 | 1.00 | IDO1 (0.58) | IDO1EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL21496550 | 1.00 | IDO1 (0.58) | IDO1EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL21496552 | 0.86 | IDO1 (0.73) | IDO1EPHX2MEN1MAPTKMT2A | |
| SCHEMBL21496551 | 0.86 | IDO1 (0.73) | IDO1EPHX2MEN1MAPTKMT2A | |
| SCHEMBL24118231 | 0.86 | IDO1 (0.75) | IDO1LMNANPSR1 | |
| SCHEMBL30056080 | 0.86 | IDO1 (0.75) | IDO1LMNANPSR1 | |
| SCHEMBL30055221 | 0.86 | IDO1 (0.75) | IDO1LMNANPSR1 | |
| SCHEMBL24118077 | 0.86 | IDO1 (0.75) | IDO1LMNANPSR1 | |
| SCHEMBL30056965 | 0.86 | IDO1 (0.74) | IDO1MEN1KMT2ARAB9A | |
| SCHEMBL21504262 | 0.84 | IDO1 (0.61) | IDO1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781142-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp&Dohme Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | claimed |
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885EPHX2 805/4885SMN1; SMN2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.